Cargando…
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632214/ https://www.ncbi.nlm.nih.gov/pubmed/34858324 http://dx.doi.org/10.3389/fendo.2021.731631 |
_version_ | 1784607714008104960 |
---|---|
author | Mirallas, Oriol Filippi-Arriaga, Francesca Hernandez Hernandez, Irene Aubanell, Anton Chaachou, Anas Garcia-Alvarez, Alejandro Hernando, Jorge Martínez-Saez, Elena Biagetti, Betina Capdevila, Jaume |
author_facet | Mirallas, Oriol Filippi-Arriaga, Francesca Hernandez Hernandez, Irene Aubanell, Anton Chaachou, Anas Garcia-Alvarez, Alejandro Hernando, Jorge Martínez-Saez, Elena Biagetti, Betina Capdevila, Jaume |
author_sort | Mirallas, Oriol |
collection | PubMed |
description | Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide. |
format | Online Article Text |
id | pubmed-8632214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86322142021-12-01 Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report Mirallas, Oriol Filippi-Arriaga, Francesca Hernandez Hernandez, Irene Aubanell, Anton Chaachou, Anas Garcia-Alvarez, Alejandro Hernando, Jorge Martínez-Saez, Elena Biagetti, Betina Capdevila, Jaume Front Endocrinol (Lausanne) Endocrinology Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide. Frontiers Media S.A. 2021-11-11 /pmc/articles/PMC8632214/ /pubmed/34858324 http://dx.doi.org/10.3389/fendo.2021.731631 Text en Copyright © 2021 Mirallas, Filippi-Arriaga, Hernandez Hernandez, Aubanell, Chaachou, Garcia-Alvarez, Hernando, Martínez-Saez, Biagetti and Capdevila https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Mirallas, Oriol Filippi-Arriaga, Francesca Hernandez Hernandez, Irene Aubanell, Anton Chaachou, Anas Garcia-Alvarez, Alejandro Hernando, Jorge Martínez-Saez, Elena Biagetti, Betina Capdevila, Jaume Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report |
title | Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report |
title_full | Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report |
title_fullStr | Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report |
title_full_unstemmed | Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report |
title_short | Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report |
title_sort | aggressive pituitary macroadenoma treated with capecitabine and temozolomide chemotherapy combination in a patient with nelson’s syndrome: a case report |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632214/ https://www.ncbi.nlm.nih.gov/pubmed/34858324 http://dx.doi.org/10.3389/fendo.2021.731631 |
work_keys_str_mv | AT mirallasoriol aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT filippiarriagafrancesca aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT hernandezhernandezirene aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT aubanellanton aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT chaachouanas aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT garciaalvarezalejandro aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT hernandojorge aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT martinezsaezelena aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT biagettibetina aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT capdevilajaume aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport |